Non-Small Cell Lung Cancer | Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 2
Research To Practice | Oncology Videos · Dr. Neil Love
September 20, 20221h 4m
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring perspectives from Dr Lecia Sequist, including the following topics:
- Introduction: Journal Club with Lecia V Sequist, MD, MPH (0:00)
- Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an EGFR exon 19 mutation— Adam R Miller, MD (19:26)
- Case: A man in his late 70s with metastatic adenocarcinoma of the lung and an EGFR L858R mutation develops hemoptysis from an "escape lesion" on osimertinib — Priya Rudolph, MD, PhD (24:59)
- Case: A man in his early 70s with metastatic adenocarcinoma of the lung (PD-L1 high) and an EGFR L858R mutation experiences disease progression on pembrolizumab — Sandip Patel, MD (28:45)
- Case: A woman in her mid 60s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion with multiple brain and bone metastases (PD-L1
- Case: A woman in her mid 50s with metastatic adenocarcinoma of the lung and an EGFR mutation experiences disease progression after response to osimertinib x 3 years (PD-L1 TPS 80%) — Gigi Chen, MD (43:44)
- Case: A man in his mid 50s with adenocarcinoma of the lung and an EGFR exon 19 mutation with brain metastases and disease progression on both osimertinib and carboplatin/paclitaxel/pembrolizumab/bevacizumab (ROS fusion detected on RNA assay) — Namrata I Peswani, MD (59:12)